Clinical trial
Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult…
NCT00263744 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00263744 |
|---|---|
| Title | Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive |
| Official title | A Phase I/II Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus (HPV) Types 16 and 18, in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive |
| Lead sponsor | MedImmune LLC, Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Biological, Other |
| Interventions | MEDI 517, Aluminum hydroxide |
| Enrollment | 60 |
| Start date | Nov 1, 1999 |
| Primary completion | Apr 1, 2001 |
| Completion | Jun 1, 2001 |
| First posted | Dec 9, 2005 |
| Last update posted | Jan 8, 2009 |
At a glance
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: